Ann MacLaren

Ann MacLaren

Company: Triphase Accelerator

Job title: Executive Director, Translational Development


Phase I Pharmacokinetic (PK) & Safety Study of TRPH- 222 in Patients with Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma 3:00 pm

• Summarize the SMARTag technology and Phase 1 study design • Review of the safety and efficacy of TRPH-222 in R/R NHL • Presenting our thoughts on moving ADCs beyond the delivery of cytotoxic payloadsRead more

day: day 1 track 3 pm

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.